Leuven

• A Phase 3, Open-Label, Uncontrolled Study to Evaluate the Activity, Safety, Pharmacokinetics and Pharmacodynamics of Roxadustat for the Trea … Recruiting
  2022-501980-42-00 5 2023-12-21 Anemia associated with Chronic Kidney Disease
• C0251006 - A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06823859 IN … Recruiting
  2022-502739-20-00 5 2023-11-16 Active Idiopathic Inflammatory Myopathies (Including Dermatomyositis o
• Ulcerative Colitis: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects with Moderately to Severely Active Ulcerati … Recruiting
  2022-501788-41-00 5 2023-11-14 Ulcerative Colitis
• A phase 2, multicenter, double-blind, two-arm study of subcutaneous RO7790121 for the treatment of subjects with moderate to severe active c … Recruiting
  2023-504265-23-00 4 2023-10-23 Crohn's disease
• Evaluation of epithelial ovarian, primary peritoneal, or fallopian tube cancer treatment in first recurrance using platinum-based chemothera … Recruiting
  2022-501220-14-00 4 2023-10-17 epithelial ovarian, primary peritoneal, or fallopian tube cancer
• A study to test whether different doses of BI 764532 help people with small cell lung cancer or other neuroendocrine cancers Recruiting
  2023-504247-13-00 4 2023-10-17 Small Cell Lung Cancer
• A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Denikitug (GS-1811), an Afucosylated Anti-CCR8 Monoclonal … Recruiting
  2022-501684-40-00 3 2023-10-05 Head and Neck Squamous Cell Carcinoma, Non-Small-Cell Lung Cancer, Gas
• A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY) Recruiting
  2022-502548-12-00 5 2023-09-28 marginal zone lymphoma
• A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given with Either Cemiplimab, or Cemiplimab + Fianlimab, … Recruiting
  2022-501904-83-00 7 2023-09-11 Ovarian Cancer
• Clairleaf TM: A study to test long-term treatment with BI 1291583 in people with bronchiectasis who took part in a previous study with this … Recruiting
  2023-503290-38-00 4 2023-09-05 Bronchiectasis
• A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 days to less than … Recruiting
  2023-508218-41-00 5 2023-08-17 Autosomal Recessive Polycystic Kidney Disease
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 10 2023-07-17 Atherosclerotic cardiovascular disease in patients with ESKD
• A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting
  2022-501354-10-01 5 2023-06-21 axial spondyloarthritis
• A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of … Recruiting
  2023-504254-35-00 7 2023-06-20 Unresectable locally advanced or metastatic solid tumors: • Clear cell
• A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagn … Recruiting
  2022-501709-11-00 5 2023-06-06 Isocitrate deshydrogenase1 mutation-positive (IDH1m) acute myeloid leu
• Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting
  2022-500544-38-00 5 2023-06-05 Advanced Breast Cancer
• A Ph2 Superiority Study with InO Monotherapy vs ALLR3 for Induction Treatment of Childhood HR ALL Recruiting
  2023-509810-13-00 4 2023-05-13 Acute Lymphoblastic Leukemia (ALL)
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi … Recruiting
  2023-505277-32-00 5 2023-01-26 Diffuse Large B-Cell Lymphoma (DLBCL)
• A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis Recruiting
  2022-500345-25-00 4 2023-01-16 Moderately to severely active ulcerative colitis
• A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K in … Recruiting
  2022-501152-28-00 4 2022-12-21 Breast Cancer
• Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting
  2022-502503-30-00 5 2022-12-15 Acute lymphoblastic leukemia
• A Phase 3 Study to Investigate the Efficacy and Safety of Brepocitinib in Adults with Dermatomyositis Recruiting
  2022-500367-12-00 5 2022-11-30 Dermatomyositis
• First in human study of BAY2927088 in participants who have advanced non-small cell lung cancer (NSCLC) with mutations in the genes of epide … Recruiting
  2023-503795-24-00 7 2022-09-16 Avanced Non-Small Cell Lung Cancer
• Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnose … Recruiting
  2024-516066-11-00 5 2022-08-31 Patients with newly diagnosed, histologically confirmed, primary advan

Showing 169–192 of 1,145 trials